AN OPEN-LABEL, MULTI-CENTRE, SAFETY STUDY OF FIXED-DOSE DURVALUMAB + TREMELIMUMAB COMBINATION THERAPY OR DURVALUMAB MONOTHERAPY IN ADVANCED SOLID MALIGNANCIES (STRONG) -- CORE PROTOCOL

Registry ID

D4191C00068

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA AB

Start date

2017-11-04

Last update

2017-03-28

Conditions

• MALIGNANT SOLID TUMOURS

Related clinical trials

• A FIRST-IN-HUMAN PHASE I, NON-RANDOMIZED, OPEN-LABEL, MULTICENTER DOSE ESCALATION TRIAL OF BI 765049 AND BI 765049 + EZABENLIMAB ADMINISTERED BY REPEATED INTRAVENOUS INFUSIONS IN PATIENTS WITH MALIGNANT SOLID TUMORS EXPRESSING B7-H6
• AN OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202)
• A PILOT STUDY OF ATEZOLIZUMAB (MPDL3280A) FOLLOWING ADOPTIVE CELL TRANSFER IN ACTIVE HEMATOLOGIC OR SOLID TUMOR MALIGNANCIES
• A PHASE I DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABLITY AND PHARMACOKINETICS OF AB-16B5 IN SUBJECTS WITH AN ADVANCED SOLID MALIGNANCY.
• A PHASE I/II MULTICENTER, OPEN-LABEL STUDY OF CLR457, ADMINISTERED ORALLY IN ADULT PATIENTS WITH ADVANCED SOLID MALIGNANCIES
• "A PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF AGS-22M6E GIVEN AS MONOTHERAPY FOLLOWED BY EXPANSION COHORTS IN SUBJECTS WITH MALIGNANT SOLID TUMORS THAT EXPRESS NECTIN-4."

View on source registry